NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Cipla Limited (NSE: CIPLA)

 
CIPLA Technical Analysis
2
As on 25th Apr 2024 CIPLA SHARE Price closed @ 1406.20 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1232.85 & Sell for SHORT-TERM with Stoploss of 1447.19 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

CIPLASHARE Price

Open 1407.00 Change Price %
High 1410.45 1 Day 8.00 0.57
Low 1384.10 1 Week 58.90 4.37
Close 1406.20 1 Month -75.05 -5.07
Volume 2027213 1 Year 496.55 54.59
52 Week High 1266.45 | 52 Week Low 862.35
 
CIPLA CURRENT MONTH FUTURE
Close 1404.15
Contracts Traded 3778450
Open Intrest 2422550
Change In O.I -47.31 %
Lot Size 650
CIPLA CURRENT MONTH OPTION
Most Active Call 1400.00
Most Active put 1380.00
Highest O.I Buildup Call 1500.00
Highest O.I Buildup Put 1450.00
Expiry Date 2024-04-25
CIPLA ALL MONTHS OPTIONS
For All CIPLA Options Click Here
 
NSE INDIA Most Active Stocks
IDEA 13.90 6.11%
YESBANK 25.95 1.96%
KOTAKBANK 1642.45 -10.87%
SOUTHBANK 30.40 4.47%
SAIL 164.95 0.18%
PNB 135.90 2.18%
TATASTEEL 167.70 1.30%
AXISBANK 1127.00 6.00%
IRFC 150.25 0.84%
IOB 66.90 5.77%
 
NSE INDIA Top Gainers Stocks
ROML 75.65 19.98%
POWERINDIA 9329.50 13.60%
GPTINFRA 211.80 12.51%
NEOGEN 1557.75 12.25%
PNC 65.00 11.02%
PNC 65.00 11.02%
PNC 65.00 11.02%
PNC 65.00 11.02%
MOIL 430.70 10.88%
GODFRYPHLP 3449.70 10.17%
 
NSE INDIA Top Losers Stocks
KOTAKBANK 1642.45 -10.87%
GLS 750.50 -9.20%
EXCEL 0.50 -9.09%
DALBHARAT 1806.45 -7.97%
WEIZMANIND 132.50 -6.85%
5PAISA 536.35 -6.77%
CELEBRITY 19.85 -6.59%
BBL 3135.00 -5.60%
BBL 3135.00 -5.60%
BBL 3135.00 -5.60%
 
 
CIPLA
Daily Charts
CIPLA
Intraday Charts
Whats New @
Bazaartrend
CIPLA
Free Analysis
 
CIPLA Important Levels Intraday
RESISTANCE1456.98
RESISTANCE1440.69
RESISTANCE1430.63
RESISTANCE1420.56
SUPPORT1391.84
SUPPORT1381.77
SUPPORT1371.71
SUPPORT1355.42
 
CIPLA Target April 2024
4th UP Target1906.59
3rd UP Target1766.86
2nd UP Target1680.49
1st UP Target1594.12
1st DOWN Target1347.68
2nd DOWN Target1261.31
3rd DOWN Target1174.94
4th DOWN Target1035.21
 
CIPLA Weekly Target
4th UP Target1605.90
3rd UP Target1522.47
2nd UP Target1470.90
1st UP Target1419.33
1st DOWN Target1272.18
2nd DOWN Target1220.61
3rd DOWN Target1169.04
4th DOWN Target1085.61
 
CIPLA Target2024
4th UP Target2077.9
3rd UP Target1811.2
2nd UP Target1646.35
1st UP Target1481.49
1st DOWN Target1011.11
2nd DOWN Target846.25
3rd DOWN Target681.4
4th DOWN Target414.7
 
 
CIPLA Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 37.27 Sideways
MFI (14) MFI is 54.26 Sideways
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is -73.69 Sideways
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Long Buy 457.11
10 Day Avg Volume Traded -22.88 % Less then 10 Day Average Volume
 
CIPLA Other Details
Segment EQ
Market Capital 737442988032.00
Sector Healthcare
Industry Drug Manufacturers-General
Offical website >
 
CIPLA Address
CIPLA
 
CIPLA Latest News
 
Your Comments and Response on Cipla Limited
 
CIPLA Business Profile
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other dosage forms consists of injectables and biosimilars. Cipla Limited has collaboration with CSIR-Indian Institute of Chemical Technology for the development of medication for the treatment of COVID-19; partnership with Karwa Ltd. for the commercialization of antibody detection kits for COVID-19; partnership with the Premier Medical Corporation Private Limited for the commercialization of the rapid antigen test kits for COVID-19; licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India. Address: Cipla House, Mumbai, India, 400013
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service